Results from Galderma’s phase IIIb trials demonstrate rapid and long-lasting effect of RelabotulinumtoxinA on crow’s feet and frown lines Press release
Galderma reports record net sales of over 3 B USD for the first nine months of 2023 with strong growth momentum across all product categories Press release
Galderma phase III data published in The New England Journal of Medicine: full Olympia 2 trial results demonstrate nemolizumab’s rapid onset of action in patients with prurigo nodularis Press release
Galderma @ EADV 2023: phase III trials demonstrate nemolizumab’s efficacy and rapid onset of action in atopic dermatitis and prurigo nodularis Press release
EADV 2023: Galderma to present new data showcasing its continued leadership in dermatology Press release
Galderma reiterates its commitment to commercialize and continue developing the broadest Injectable Aesthetics portfolio on the market, following Ipsen's recent announcement Press release
Galderma achieves record 2 B USD net sales for a six-month period in H1 2023, as it continues to demonstrate leading execution and innovation capabilities in dermatology Press release
Galderma raises approximately USD 1 billion for newly issued shares in a private placement round Press release
